1-[(6-Fluoro-3-pyridinyl)methyl]-1H-pyrazole-4-carboxylic acid | 1174666-19-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-[(6-Fluoro-3-pyridinyl)methyl]-1H-pyrazole-4-carboxylic acid
• 英文别名: 1-[(6-fluoropyridin-3-yl)methyl]pyrazole-4-carboxylic acid
• CAS: 1174666-19-3
• 化学式: C₁₀H₈FN₃O₂
• 分子量: 221.19
• InChiKey: BPVZEYJMDPIBEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  68
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS<br/>[FR] UTILISATION DE DÉRIVÉS HÉTÉROARYLCARBOXAMIDES COMME INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2017072021A1

  公开（公告）日：2017-05-04

  The present invention relates to compounds of general formula (I), wherein D 1 to D 3, -A-, n, R 1, R 2, Y 1, L and y2 are defined as in claim 1, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.

  本发明涉及一般式（I）的化合物，其中D1至D3，-A-，n，R1，R2，Y1，L和Y2的定义如权利要求书中所述，具有有价值的药理特性，特别是是血浆激肽酶的抑制剂。这些化合物适用于治疗和预防可以通过抑制血浆激肽酶而受影响的疾病，例如糖尿病并发症，特别是治疗与糖尿病视网膜病变和糖尿病黄斑水肿相关的视网膜血管通透性。
• Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity
  申请人：Vernalis (R&D) Ltd.

  公开号：US20150099736A1

  公开（公告）日：2015-04-09

  Compounds of formula (I) have checkpoint kinase 1 (CHK1) inhibitory activity: wherein R 1 , R 2 , R 5 and R 6 are independently selected from hydrogen, hydroxy, methyl, trifluoromethyl, hydroxymethyl, methoxy, trifluoromethoxy, methylamino and dimethylamino; R 3 , and R 4 are independently selected from hydrogen, hydroxy, C 1 -C 3 alkyl, fluoro-(C 1 -C 3 )-alkyl, hydroxy-(C 1 -C 3 )-alkyl, C 1 -C 3 alkoxy, fluoro-(C 1 -C 3 )-alkoxy, hydroxy-(C 1 -C 3 )-alkoxy, —N(R 11 )—R 12 , -Alk-N(R 11 )—R 12 , —O-Alk-N(R 11 )—R 12 , —C(═O)OH, carboxy-(C 1 -C 3 )-alkyl, or —C(═O)—NH—R 13 ; Alk is a straight or branched chain divalent C 1 -C 6 alkylene radical; R 7 and R 8 are independently selected from hydrogen, hydroxy, or C 1 -C 3 alkoxy; X is a straight chain divalent C 1 -C 3 alkylene radical, optionally substituted on one or more carbons by R 9 and/or R 10 ; W is selected from —C(═O)—N(—R 16 )— or —N(—R 17 )—C(═O)—; Y is hydrogen, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, or halo; and Q is selected from optionally substituted phenyl, optionally substituted cyclohexyl, or an optionally substituted 6-membered monocyclic heteroaryl ring.

  公式（I）的化合物具有检查点激酶1（CHK1）抑制活性：其中R1、R2、R5和R6分别选自氢、羟基、甲基、三氟甲基、羟甲基、甲氧基、三氟甲氧基、甲基氨基和二甲氨基；R3和R4分别选自氢、羟基、C1-C3烷基、氟代（C1-C3）烷基、羟基（C1-C3）烷基、C1-C3烷氧基、氟代（C1-C3）烷氧基、羟基（C1-C3）烷氧基、-N（R11）-R12，-Alk-N（R11）-R12，-O-Alk-N（R11）-R12，-C（=O）OH，羧基（C1-C3）烷基或-C（=O）-NH-R13；Alk是直链或支链的二价C1-C6烷基基团；R7和R8分别选自氢、羟基或C1-C3烷氧基；X是直链的二价C1-C3烷基基团，可在一个或多个碳上取代R9和/或R10；W选自-C（=O）-N（-R16）-或-N（-R17）-C（=O）-；Y选自氢、C1-C3烷基、C1-C3烷氧基或卤素；Q选自可选取代的苯基、可选取代的环己基或可选取代的6元单环杂芳基。
• Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10399961B2

  公开（公告）日：2019-09-03

  The present invention relates to compounds of general formula I, wherein D1 to D3, A, R1, R2, Y and n are defined as in claim 1, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.

  本发明涉及通式 I 的化合物，其中 D1 至 D3、A、R1、R2、Y 和 n 的定义如权利要求 1 所述，这些化合物具有宝贵的药理特性，尤其是血浆钙化蛋白抑制剂。这些化合物适用于治疗和预防可受血浆钙化蛋白抑制剂影响的疾病，如糖尿病并发症，特别是治疗与糖尿病视网膜病变和糖尿病黄斑水肿相关的视网膜血管通透性。
• Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
  申请人：Vernalis (R&D) Ltd.

  公开号：US10696652B2

  公开（公告）日：2020-06-30

  A method of treating a mammal suffering from a cancer responsive to inhibition of protein kinase activity, by administering to the mammal an amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, effective to inhibit protein kinase activity, wherein the compound of formula (I) is:

  一种治疗患有对蛋白激酶活性抑制有反应的癌症的哺乳动物的方法，向该哺乳动物施用一定量的式(I)化合物或其药学上可接受的盐，以有效抑制蛋白激酶活性，其中式(I)化合物是：
• INDOLYL-PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY
  申请人：Vernalis (R&D) Ltd.

  公开号：EP2294065B1

  公开（公告）日：2014-03-19